S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
The Market Crash Shield is A.I. (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
The Market Crash Shield is A.I. (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:SLS

SELLAS Life Sciences Group - SLS Stock Forecast, Price & News

$1.43
+0.05 (+3.62%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.40
▼
$1.48
50-Day Range
$1.18
▼
$3.86
52-Week Range
$1.17
▼
$7.37
Volume
229,202 shs
Average Volume
489,215 shs
Market Capitalization
$40.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

SELLAS Life Sciences Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
389.5% Upside
$7.00 Price Target
Short Interest
Healthy
4.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.66) to ($0.96) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

576th out of 1,004 stocks

Pharmaceutical Preparations Industry

277th out of 489 stocks

See Top Rated MarketRank™ Stocks Here

SLS stock logo

About SELLAS Life Sciences Group (NASDAQ:SLS) Stock

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

SLS Stock News Headlines

March 24, 2023 | americanbankingnews.com
Cantor Fitzgerald Comments on SELLAS Life Sciences Group, Inc.'s FY2023 Earnings (NASDAQ:SLS)
March 18, 2023 | markets.businessinsider.com
Maxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)
April 1, 2023 | Vantage Point (Ad)
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
March 17, 2023 | finanznachrichten.de
SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023 | msn.com
SELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-line
March 16, 2023 | finance.yahoo.com
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
March 7, 2023 | finance.yahoo.com
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
February 24, 2023 | msn.com
Why Sellas Life Sciences Shares Are Nosediving
April 1, 2023 | Vantage Point (Ad)
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
February 24, 2023 | finance.yahoo.com
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
February 24, 2023 | finance.yahoo.com
Sellas Life Sciences raises $20 million from public offering of stock, warrants
February 24, 2023 | finance.yahoo.com
Sellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offering
February 5, 2023 | finance.yahoo.com
Here's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situation
January 19, 2023 | finance.yahoo.com
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
January 5, 2023 | finance.yahoo.com
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
December 13, 2022 | finance.yahoo.com
SELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients
December 13, 2022 | finance.yahoo.com
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
December 8, 2022 | msn.com
Looking Into SELLAS Life Sciences Gr's Recent Short Interest
December 8, 2022 | technews.tmcnet.com
SELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
December 8, 2022 | finance.yahoo.com
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
December 6, 2022 | finance.yahoo.com
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
December 1, 2022 | finance.yahoo.com
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model
November 30, 2022 | finance.yahoo.com
SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
November 16, 2022 | finance.yahoo.com
SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)
November 15, 2022 | finance.yahoo.com
SELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated
November 14, 2022 | finance.yahoo.com
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
November 14, 2022 | finance.yahoo.com
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
See More Headlines
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

SLS Company Calendar

Last Earnings
11/12/2021
Today
4/01/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLS
CUSIP
N/A
CIK
1390478
Web
www.sellaslifesciences.com
Phone
(646) 200-5278
Fax
441-400-2875
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+389.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,300,000.00
Net Margins
N/A
Pretax Margin
-4,130.10%
Return on Equity
-407.61%
Return on Assets
-164.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.14
Quick Ratio
1.14

Sales & Book Value

Annual Sales
$1 million
Price / Sales
40.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
6.22

Miscellaneous

Outstanding Shares
28,300,000
Free Float
27,992,000
Market Cap
$40.47 million
Optionable
Not Optionable
Beta
2.30

Key Executives

  • Angelos M. Stergiou
    President, Chief Executive Officer & Director
  • John T. Burns
    SVP, Chief Financial Officer & Accounting Officer
  • Dragan Cicic
    Senior Vice President-Clinical Development
  • Barbara A. Wood
    Secretary, Executive VP & General Counsel
  • Andrew Elnatan
    VP, Head-Regulatory Affairs & Chemistry

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SLS Stock - Frequently Asked Questions

Should I buy or sell SELLAS Life Sciences Group stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLS shares.
View SLS analyst ratings or view top-rated stocks.

What is SELLAS Life Sciences Group's stock price forecast for 2023?

2 equities research analysts have issued 1 year target prices for SELLAS Life Sciences Group's stock. Their SLS share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 389.5% from the stock's current price.
View analysts price targets for SLS or view top-rated stocks among Wall Street analysts.

How have SLS shares performed in 2023?

SELLAS Life Sciences Group's stock was trading at $2.36 on January 1st, 2023. Since then, SLS shares have decreased by 39.4% and is now trading at $1.43.
View the best growth stocks for 2023 here.

When is SELLAS Life Sciences Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our SLS earnings forecast.

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09.

When did SELLAS Life Sciences Group's stock split?

SELLAS Life Sciences Group shares reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What is SELLAS Life Sciences Group's stock symbol?

SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SELLAS Life Sciences Group's stock price today?

One share of SLS stock can currently be purchased for approximately $1.43.

How much money does SELLAS Life Sciences Group make?

SELLAS Life Sciences Group (NASDAQ:SLS) has a market capitalization of $40.47 million and generates $1 million in revenue each year. The company earns $-41,300,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How can I contact SELLAS Life Sciences Group?

SELLAS Life Sciences Group's mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The official website for the company is www.sellaslifesciences.com. The company can be reached via phone at (646) 200-5278, via email at ir@sellaslife.com, or via fax at 441-400-2875.

This page (NASDAQ:SLS) was last updated on 4/1/2023 by MarketBeat.com Staff